CRG-002 (allogeneic iPSC-derived pancreatic islet cells)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CRG-002 (allogeneic iPSC-derived pancreatic islet cells), covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events [EARLY_Phase 1]